<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783766</url>
  </required_header>
  <id_info>
    <org_study_id>JX01001</org_study_id>
    <secondary_id>CTR20210291</secondary_id>
    <nct_id>NCT04783766</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics Study of CK-3773274</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CK-3773274 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to:&#xD;
&#xD;
        1. Learn about the safety of CK-3773274 after a single dose and multiple doses in Chinese&#xD;
           healthy adult subjects.&#xD;
&#xD;
        2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses.&#xD;
&#xD;
        3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses.&#xD;
&#xD;
        4. Determine the effect of doses of CK-3773274 on the pumping function of the heart.&#xD;
&#xD;
        5. Evaluate the effect CYP2D6 genetic polymorphisms on how the body metabolizes CK-3773274.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2021</start_date>
  <completion_date type="Actual">August 5, 2021</completion_date>
  <primary_completion_date type="Actual">August 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of Adverse Event (AE), Serious Adverse Event (SAE)</measure>
    <time_frame>SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduced Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of CK-3773274 after single and multiple ascending doses</measure>
    <time_frame>SAD Cohorts: Day-1 - Day10; MD Cohort: Day-1 - Day 23</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Obstructive Hypertrophic Cardiomyopathy</condition>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>CK-3773274 for Single Ascending Dose (SAD) Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of CK-3773274</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator for SAD Cohorts</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CK-3773274 for Multiple Dose (MD) Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of CK-3773274</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator for MD Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive multiple doses of placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-3773274</intervention_name>
    <description>CK-3773274- Tablets</description>
    <arm_group_label>CK-3773274 for Multiple Dose (MD) Cohort</arm_group_label>
    <arm_group_label>CK-3773274 for Single Ascending Dose (SAD) Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo- Tablets</description>
    <arm_group_label>Placebo comparator for MD Cohort</arm_group_label>
    <arm_group_label>Placebo comparator for SAD Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy Chinese males and females between 18 and 45 years of age, inclusive&#xD;
&#xD;
          2. Body weight ≥50kg and body mass index (BMI) within 18 to 26 kg/m2, inclusive&#xD;
&#xD;
          3. Acoustic windows adequate for accurate transthoracic echocardiograms&#xD;
&#xD;
          4. Normal cardiac structure and function, as determined by the cardiologist, or if&#xD;
             abnormalities are present, the finding is not clinically significant as determined by&#xD;
             the cardiologist&#xD;
&#xD;
          5. LVEF ≥65 percent at screening, and LVEF ≥60 percent at Day-1&#xD;
&#xD;
          6. Normal ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs&#xD;
&#xD;
          2. Subjects with breast implants that may impede echocardiography&#xD;
&#xD;
          3. A clinically significant illness within 4 weeks prior to admission to the CRU&#xD;
&#xD;
          4. Inability to swallow tablets&#xD;
&#xD;
          5. Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or&#xD;
             beverages within 48 hours prior to admission to the CRU&#xD;
&#xD;
          6. Poor peripheral venous access&#xD;
&#xD;
          7. Any blood donation within 60 days prior to admission to the CRU, or any plasma&#xD;
             donation within 30 days prior to admission to the CRU, or receipt of blood products&#xD;
             within 2 months prior to admission to the CRU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CK-274</keyword>
  <keyword>Obstructive hypertrophic cardiomyopathy</keyword>
  <keyword>CK-3773274</keyword>
  <keyword>oHCM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

